Evelo Biosciences, Inc. EVLO
We take great care to ensure that the data presented and summarized in this overview for Evelo Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EVLO
Top Purchases
Top Sells
About EVLO
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at EVLO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,811
-7.52%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
172
-0.96%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,103
-15.45%
|
$0
$0.33 P/Share
|
|
Nov 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
3,163
-10.95%
|
$0
$0.33 P/Share
|
|
Nov 07
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+21.26%
|
-
|
|
Nov 07
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,172
+6.14%
|
-
|
|
Nov 07
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+24.45%
|
-
|
|
Nov 07
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
6,625
+18.65%
|
-
|
|
Nov 02
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,999
-18.54%
|
$0
$0.33 P/Share
|
|
Nov 02
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,854
-33.53%
|
$0
$0.33 P/Share
|
|
Nov 02
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
6,854
-23.53%
|
$0
$0.33 P/Share
|
|
Nov 01
2023
|
Marella Thorell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+36.69%
|
-
|
|
Nov 01
2023
|
Duncan Mc Hale Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+37.95%
|
-
|
|
Nov 01
2023
|
Mark Bodmer CSO, President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+30.03%
|
-
|
|
Sep 28
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
1,996
-10.64%
|
$5,988
$3.94 P/Share
|
|
Sep 27
2023
|
Simba Gill President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+44.44%
|
-
|
|
Aug 08
2023
|
Marella Thorell Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,004
-18.1%
|
$18,036
$9.51 P/Share
|
|
Aug 08
2023
|
Duncan Mc Hale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,434
-30.19%
|
$30,906
$9.51 P/Share
|
|
Aug 08
2023
|
Simba Gill President & CEO |
SELL
Open market or private sale
|
Direct |
342
-8.35%
|
$3,078
$9.51 P/Share
|
|
Aug 08
2023
|
Mark Bodmer CSO, President of R&D |
SELL
Open market or private sale
|
Direct |
3,128
-15.84%
|
$28,152
$9.51 P/Share
|